Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder by  et al.
                          the 23 and Me Research Team, ADHD Working Group of the Psychiatric
Genomics Consortium (PGC), Early Lifecourse & Genetic Epidemiology
(EAGLE) Consortium, Demontis, D., Walters, R. K., Martin, J., ... Medland,
S. E. (2019). Discovery of the first genome-wide significant risk loci for
attention deficit/hyperactivity disorder. Nature Genetics, 51(1), 63-75.
https://doi.org/10.1038/s41588-018-0269-7
Peer reviewed version
License (if available):
Other
Link to published version (if available):
10.1038/s41588-018-0269-7
Link to publication record in Explore Bristol Research
PDF-document
This is the accepted author manuscript (AAM). The final published version (version of record) is available online
via Springer Nature at https://doi.org/10.1038/s41588-018-0269-7 . Please refer to any applicable terms of use
of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
Reprints and permissions information is available at www.nature.com/reprints
Correspond with: Benjamin M. Neale (bneale@broadinstitute.org), Analytic and Translational Genetics Unit, Department of 
Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA. Anders D. Børglum 
(anders@biomed.au.dk) Department of Biomedicine - Human Genetics, Aarhus University, Aarhus, Denmark. Stephen V. Faraone 
(sfaraone@childpsychresearch.org)Departments of Psychiatry and Neuroscience and Physiology, SUNY Upstate Medical University, 
Syracuse, New York, USA.†Equal contributions.
*Co-last authors.
Author Contributions
Analysis:
DD, RKW, JMar, MM, TDA, CC, NE, MG, KLG, MEH, DPH, HHai, JMal, ARM, JP, DSP, TP, SR, EBR, FKS, HS, PT, GBW, HW, 
DB, DG, CM, PR, PFS, JT, SEM, KS. ADB and BMN supervised and coordinated analyses.
Sample and/or data provider and processing:
DD, RKW, JMar, MM, EA, GB, RB, JB-G, MB-H, FC, KC, AD, NE, JGo, JGr, OOG, CSH, MVH, JMal, NGM, JMo, CBP, MGP, 
JBP, SR, CS, MJW, OAA, PA, CB, DB, BC, SD, BF, JGe, HHak, JH, HK, JK, KL, KPL, CM, AR, LAR, RS, PS, EJSSB, AT, JT, IW, 
SEM, DMH, OM, PBM, ADB, ADHD Working Group of the Psychiatric Genomics Consortium, Early Lifecourse & Genetic 
Epidemiology (EAGLE) Consortium, 23andMe Research Team.
Core PI group:
SEM, KS, MN, DMH, TW, OM, PBM, MJD, SVF, ADB, BMN.
Core writing group:
DD, RKW, JM, SVF, ADB, BMN.
Direction of study: ADB, SVF, BMN.
All authors contributed with critical revision of the manuscript.
Competing Interests
In the past year, Dr. Faraone received income, potential income, travel expenses continuing education support and/or research support 
from Lundbeck, Rhodes, Arbor, KenPharm, Ironshore, Shire, Akili Interactive Labs, CogCubed, Alcobra, VAYA, Sunovion, 
Genomind and Neurolifesciences. With his institution, he has US patent US20130217707 A1 for the use of sodium-hydrogen 
exchange inhibitors in the treatment of ADHD. In previous years, he received support from: Shire, Neurovance, Alcobra, Otsuka, 
McNeil, Janssen, Novartis, Pfizer and Eli Lilly. Dr. Faraone receives royalties from books published by Guilford Press: Straight Talk 
about Your Child’s Mental Health, Oxford University Press: Schizophrenia: The Facts and Elsevier: ADHD: Non-Pharmacologic 
Interventions. He is principal investigator of www.adhdinadults.com.
Dr. Neale is a member of Deep Genomics Scientific Advisory Board and has received travel expenses from Illumina. He also serves as 
a consultant for Avanir and Trigeminal solutions.
Olafur O. Gudmundsson, G. Bragi Walters, Hreinn Stefansson and Kari Stefansson are employees of deCODE genetics/Amgen.
Nicholas Eriksson, Joyce Y Tung, and the 23andMe Research Team are employees of 23andMe, Inc., and hold stock or stock options 
in 23andMe.
Dr. Rohde has received honoraria, has been on the speakers' bureau/advisory board and/or has acted as a consultant for Eli-Lilly, 
Janssen-Cilag, Novartis, Medice and Shire in the last three years. He receives authorship royalties from Oxford Press and ArtMed. He 
also received travel award for taking part of 2015 WFADHD meeting from Shire. The ADHD and Juvenile Bipolar Disorder 
Outpatient Programs chaired by him received unrestricted educational and research support from the following pharmaceutical 
companies in the last three years: Eli-Lilly, Janssen-Cilag, Novartis, and Shire.
Over the last three years Dr. Sonuga-Barke has received speaker fees, consultancy, research funding and conference support from 
Shire Pharma and speaker fees from Janssen Cilag. He has received consultancy fees from Neurotech solutions, Aarhus University, 
Copenhagen University and Berhanderling, Skolerne, Copenhagen, KU Leuven. Book royalties from OUP and Jessica Kingsley. He is 
the editor-in-chief of the Journal of Child Psychology and Psychiatry for which his University receives financial support.
Dr. Franke has received educational speaking fees from Merz and Shire.
Dr. Schachar’s disclosures: ehave equity and advisory board, Ironshore Pharmaceuticals Advisory Board.
Dr. Reif has received a research grant from Medice, and speaker’s honorarium from Medice and Servier.
Dr. Haavik has received speaker fees from Shire, Lilly and Novartis.
Dr. Kranzler has been an advisory board member, consultant, or CME speaker for Alkermes, Indivior, and Lundbeck. He is also a 
member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, which was supported in the last 
three years by AbbVie, Alkermes, Ethypharm, Indivior, Lilly, Lundbeck, Otsuka, Pfizer, Arbor, and Amygdala Neurosciences.
Drs. Kranzler and Gelernter are named as inventors on PCT patent application #15/878,640 entitled: "Genotype-guided dosing of 
opioid agonists," filed January 24, 2018.
Dr Asherson received honoraria paid to King's College London by Shire, Flynn Pharma, Lilly, Janssen, Novartis and Lunbeck for 
research, speaker fees, education events, advisory board membership or consultancy.
Dr. Andreassen has received speaker fees from Lundbeck and Sunovion. Dr Kuntsi has received speaker’s honorarium from Medice; 
all funds are received by King’s College London and used for studies of ADHD.
Thomas Werge has acted as lecturer and scientific advisor to H. Lundbeck A/S
Availability of genotype data and summary statistics
For access to genotypes from the PGC cohorts and the iPSYCH sample interested researchers should contact the lead PIs (iPSYCH: 
lead PI Anders D. Børglum; PGC: Benjamin Neale and Stephen Faraone). Summary statitistics can be downloaded from:
HHS Public Access
Author manuscript
Nat Genet. Author manuscript; available in PMC 2019 July 01.
Published in final edited form as:
Nat Genet. 2019 January ; 51(1): 63–75. doi:10.1038/s41588-018-0269-7.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Discovery of the first genome-wide significant risk loci for 
https://www.med.unc.edu/pgc/results-and-downloads
http://ipsych.au.dk/downloads/
http://www.wikigenes.org/e/art/e/348.html
Reporting summary
Further information about study design is available in the Life Sciences Reporting Summary linked to this article.
Supplementary Information is linked to the online version of the paper at www.nature.com/nature
Consortium Members
Consortium authors are listed alphabetically by surname for each contributing group.
ADHD Working Group of the Psychiatric Genomics Consortium (PGC)
Özgür Albayrak69,70 Richard J.L. Anney71 Maria Jesús Arranz72 Tobias J. Banaschewski73 Claiton Bau56,74 Joseph 
Biederman75,76 Jan K. Buitelaar77,78 Miguel Casas79,80,81,82 Alice Charach83 Jennifer Crosbie83 Astrid Dempfle84 Alysa E. 
Doyle85,86 Richard P. Ebstein87 Josephine Elia88,89 Christine Freitag90 Manuel Föcker69 Michael Gill91 Eugenio Grevet56,55 
Ziarih Hawi92 Johannes Hebebrand69 Beate Herpertz-Dahlmann93 Amaia Hervas72 Anke Hinney69 Sarah Hohmann73 Peter 
Holmans71 Mara Hutz74 Abel Ickowitz83 Stefan Johansson94 Lindsey Kent95 Sarah Kittel-Schneider96 Nanda Lambregts-
Rommelse97 Gerd Lehmkuhl98 Sandra K. Loo99 James J. McGough100 Jobst Meyer101 Eric Mick102 Frank Middletion103 Ana 
Miranda104 Nina Roth Mota56,105 Fernando Mulas106 Aisling Mulligan107 Freimer Nelson108 T. Trang Nguyen109 Robert D. 
Oades110 Michael C. O'Donovan71 Michael J. Owen71 Haukur Palmason111 Josep Antoni Ramos-Quiroga81,112,113,37 Tobias J. 
Renner114,115 Marta Ribasés81,112,37 Marcella Rietschel116 Olga Rivero49 Jasmin Romansos117 Marcel Romansos118 Aribert 
Rothenberger119 Herbert Royers120 Christina Sánchez-Mora81,112,37 André Scherag121,122 Benno G. Schimmelmann123 Helmut 
Schäfer109 Joseph Sergeant124 Judith Sinzig98,125 Susan L. Smalley126 Hans-Christoph Steinhausen127,128,129 Margaret 
Thompson130 Alexandre Todorov131 Alejandro Arias Vasquez132 Susanne Walitza133,117 Yufeng Wang134 Andreas Warnke117 
Nigel Williams135 Stephanie H. Witt116 Li Yang134 Tetyana Zayats44,136 Yanli Zhang-James103
Early Lifecourse & Genetic Epidemiology (EAGLE) Consortium
George Davey Smith137 Gareth E. Davies34,138 Erik A. Ehli138 David M. Evans137,139 Iryna O. Fedko34 Corina U. 
Greven140,78,141 Maria M. Groen-Blokhuis142 Monica Guzens143,144,37,145 Anke R. Hammerschlag146 Catharina A. 
Hartman147 Joachim Heinrich148,149 Jouke Jan Hottenga150 James Hudziak151,152,153,154 Astanand Jugessur155,156 John P. 
Kemp137,139 Eva Krapohl141 Mario Murcia37,157 Ronny Myhre158 Ilja M. Nolte159 Dale R. Nyholt160 Johan Ormel147 Klaasjan 
G. Ouwens34 Irene Pappa145,161 Craig E. Pennell162 Robert Plomin141 Susan Ring137,163 Marie Standl148 Evie 
Stergiakouli137,139 Beate St Pourcain137,164 Camilla Stoltenberg165 Jordi Sunyer144,166,167 Elisabeth Thiering148,168 Henning 
Tiemeier153 Carla M.T. Tiesler148,168 Nicholas J. Timpson137 Maciej Trzaskowski29 Peter Johannes van der Most159 Natalia 
Vilor-Tejedor143,144,166 Carol A. Wang162 Andrew J.O. Whitehouse169 Huiying Zhao160
23andMe Research Team
Michelle Agee16 Babak Alipanahi16 Adam Auton16 Robert K. Bell16 Katarzyna Bryc16 Sarah L. Elson16 Pierre Fontanillas16 
Nicholas A. Furlotte16 David A. Hinds16 Bethann S. Hromatka16 Karen E. Huber16 Aaron Kleinman16 Nadia K. Litterman16 
Matthew H. McIntyre16 Joanna L. Mountain16 Carrie A.M. Northover16 Steven J. Pitts16 J. Fah Sathirapongsasuti16 Olga V. 
Sazonova16 Janie F. Shelton16 Suyash Shringarpure16 Chao Tian16 Vladimir Vacic16 Catherine H. Wilson16
69 Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital Essen, University of 
Duisburg-Essen, Essen, Germany
70 Department of Psychosomatic Medicine and Psychotherapy, Hannover Medical School (MHH), Hannover, Germany
71 MRC Centre for Neuropsychiatric Genetics and Genomics, Department of Psychological Medicine and Neurology, School of 
Medicine, Cardiff University, Cardiff, Wales, UK
72 University Hospital Mutua Terrassa, Barcelona, Spain
73 Department of Child and Adolescent Psychiatry, Central Institute of Mental Health and Mannheim Medical Faculty, University of 
Heidelberg, Heidelberg, Germany
74 Department of Genetics, Instituto de Biociências, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
75 Pediatric Psychopharmacology Unit, Massachusetts General Hospital, Boston, MA, USA
76 Department of Psychiatry, Harvard Medical School, Boston, MA, USA
77 Department of Cognitive Neuroscience, Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Centre, 
Nijmegen, The Netherlands
78 Karakter Child and Adolescent Psychiatry University Center, Nijmegen, The Netherlands
79 Universitat Autònoma de Barcelona, Barcelona, Spain
80 Programa Corporatiu “Neurodevelopment Disorders along Life Span”, Institut Català de la Salut, Barcelona, Spain
81 Department of Psychiatry, Hospital Universitari Vall d’Hebron, Barcelona, Spain
82 Clinica Galatea y PAIMM, Mental Health Program for Impaired Physicians, Barcelona, Spain
83 The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
84 Institute of Medical Informatics and Statistics, Kiel University, Kiel, Germany
85 Massachusetts General Hospital, Boston, MA, USA.
86 Harvard Medical School, Boston, MA, USA.
Demontis et al. Page 2
Nat Genet. Author manuscript; available in PMC 2019 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
attention-deficit/hyperactivity disorder
87 National University of Singapore, Singapore
88 Department of Pediatrics, Nemours A.I. duPont Hospital for Children, Wilmington, DE, USA
89 Department of Psychiatry, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA
90 Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital Frankfurt, Goethe 
University, Frankfurt am Main, Germany
91 Department of Psychiatry, Trinity College Dublin, Trinity Centre for Health Sciences, St. James’s Hospital, Dublin 8, Ireland
92 School of Psychological Sciences and Monash Institute for Cognitive and Clinical Neurosciences, Monash University, Melbourne, 
Australia
93 Department of Child & Adolescent Psychiatry & Psychosomatic Medicine of University Clinics, RWTH Aachen, Aachen, 
Germany
94 K.G.Jebsen Centre for Psychiatric Disorders, Department of Clinical Science, University of Bergen, Bergen, Norway
95 University of St Andrews, St Andrews, UK
96 Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital, Frankfurt Germany
97 Karakter Child and Adolescent Psychiatry University Center and department of Psychiatry, Donders Institute for Brain, Cognition 
and Behavior, Radboud University Nijmegen Medical Centre, Nijmegen, 6500 HB, The Netherlands
98 Department of Child and Adolescent Psychiatry, University of Cologne, Cologne, Germany
99 Department of Psychiatry, University of California, Los Angeles, Los Angeles, CA, USA
100 Semel Institute for Neuroscience & Human Behavior, David Geffen School of Medicine, University of California at Los Angeles, 
Los Angeles, CA, USA
101 Institute of Psychobiology, Department of Neurobehavioral Genetics, University of Trier, Trier, Germany
102 Quantitative Health Sciences University of Massachusetts Medical School, Worcester, MA 01655, USA
103 Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY, USA
104 Department of Developmental and Educational Psychology, University of Valencia, Spain
105 Department of Human Genetics, Radboud University Medical Center, Nijmegen, Netherlands
106 Instituto Valenciano de Neurologia Pediatrica (INVANEP), Valencia, Spain
107 Senior Lecturer in Child and Adolescent Psychiatry, University College Dublin, Ireland
108 Center for Neurobehavioral Genetics, Semel Institute for Neuroscience & Human Behavior, University of California at Los 
Angeles, Los Angeles, CA, USA
109 University of Marburg, Marburg, Germany
110 Clinic for Child and Adolescent Psychiatry and Psychotherapy, University of Duisburg-Essen, Essen, Germany
111 Landspitali National University Hospital, Reykjavik, Iceland
112 Psychiatric Genetics Unit, Group of Psychiatry, Mental Health and Addiction, Vall d’Hebron Research Institute (VHIR), 
Universitat Autònoma de Barcelona, Barcelona, Spain
113 Department of Psychiatry and Legal Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain
114 Department of Child and Adolescent Psychiatry, Universitätsklinikum Tübingen, Tübingen, Germany
115 Division of Molecular Psychiatry, ADHD Clinical Research Unit, Department of Psychiatry, Psychosomatics and Psychotherapy, 
University of Wuerzburg, Germany
116 Central Institute of Mental Health, Department of Genetic Epidemiology in Psychiatry, Medical Faculty Mannheim, University of 
Heidelberg, Mannheim, Germany
117 Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University of Wuerzburg, Wuerzburg, 
Germany
118 University Hospital of Würzburg, Center of Mental Health, Department of Child and Adolescent Psychiatry, Psychosomatics and 
Psychotherapy, Wuerzburg, Germany
119 Child and Adolescent Psychiatry/Psychotherapy, University Medical Center, Goettingen, Germany
120 Ghent University, Dunantlaan, Ghent, B-9000 Belgium
121 Institute for Medical Informatics, Biometry and Epidemiology (IMIBE), University of Duisburg-Essen, Essen, Germany
122 Clinical Epidemiology, Integrated Research and Treatment Center, Center for Sepsis Control and Care (CSCC), Jena University 
Hospital, Jena, Germany
123 University Hospital of Child- and Adolescent Psychiatry, University of Bern, Bern, Switzerland
124 Vrije Universiteit, De Boelelaan, Amsterdam, The Netherlands;
125 Department of Child and Adolescent Psychiatry and Psychotherapy, LVR – Clinic Bonn, Bonn, Germany
126 University of California Los Angeles
127 University of Zurich, Switzerland
128 Aalborg University, Denmark
129 University of Basel, Switzerland
130 University of Southampton UK
131 Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, USA
132 Department of Psychiatry & Human Genetics, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical 
Center, Nijmegen, The Netherlands
133 Department of Child and Adolescent Psychiatry, University of Zurich, Zurich, Switzerland
Demontis et al. Page 3
Nat Genet. Author manuscript; available in PMC 2019 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A full list of authors and affiliations appears at the end of the article.
Abstract
Attention-Deficit/Hyperactivity Disorder (ADHD) is a highly heritable childhood behavioral 
disorder affecting 5% of children and 2.5% of adults. Common genetic variants contribute 
substantially to ADHD susceptibility, but no variants have been robustly associated with ADHD. 
We report a genome-wide association meta-analysis of 20,183 diagnosed ADHD cases and 35,191 
controls that identifies variants surpassing genome-wide significance in 12 independent loci, 
revealing new and important information on the underlying biology of ADHD. Associations are 
enriched in evolutionarily constrained genomic regions, loss-of-function intolerant genes and 
around brain-expressed regulatory marks. Analyses of three replication studies; a cohort of 
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diagnosed ADHD, a self-reported ADHD sample and a meta-analysis of quantitative measures of 
ADHD symptoms in the population, support these findings while highlighting study-spcific 
differences on genetic overlap with educational attainment. Strong concordance with GWAS of 
quantitative population measures of ADHD symptoms supports that clinical diagnosis of ADHD is 
an extreme expression of continuous heritable traits.
Introduction
Attention-Deficit/Hyperactivity Disorder (ADHD) is a neurodevelopmental psychiatric 
disorder, that affects around 5% of children and adolescents and 2.5% of adults worldwide1. 
ADHD is often persistent and markedly impairing with increased risk of harmful outcomes 
such as injuries2, traffic accidents3, increased health care utilization4,5, substance abuse6, 
criminality7, unemployment8, divorce4, suicide9, AIDS risk behaviors8, and premature 
mortality10. Epidemiologic and clinical studies implicate genetic and environmental risk 
factors that affect the structure and functional capacity of brain networks involved in 
behavior and cognition1, in the etiology of ADHD.
Consensus estimates from over 30 twin studies indicate that the heritability of ADHD is 70–
80% throughout the lifespan11,12 and that environmental risks are those not shared by 
siblings13. Twin studies also suggest that diagnosed ADHD represents the extreme tail of 
one or more heritable quantitative traits14. Additionally, family and twin studies report 
genetic overlap between ADHD and other conditions including antisocial personality 
disorder/behaviours15, cognitive impairment16, autism spectrum disorder17,18, 
schizophrenia19, bipolar disorder20, and major depressive disorder21.
Thus far genome-wide association studies (GWASs) to identify common DNA variants that 
increase the risk of ADHD have not been successful22. Nevertheless, genome-wide SNP 
heritability estimates range from 0.10 – 0.2823,24 supporting the notion that common 
variants comprise a significant fraction of the risk underlying ADHD25 and that with 
increasing sample size, and thus increasing statistical power, genome-wide significant loci 
will emerge.
Previous studies have demonstrated that the common variant risk, also referred to as the 
single nucleotide polymorphism (SNP) heritability, of ADHD is also associated with 
depression25, conduct problems26, schizophrenia27, continuous measures of ADHD 
symptoms28,29 and other neurodevelopmental traits29 in the population. Genetic studies of 
quantitative ADHD symptom scores in children further support the hypothesis that ADHD is 
the extreme of a quantitative trait30.
Here we present a genome-wide meta-analysis identifying the first genome-wide significant 
loci for ADHD using a combined sample of 55,374 individuals from an international 
collaboration. We also strengthen the case that the clinical diagnosis of ADHD is the 
extreme expression of one or more heritable quantitative traits, at least as it pertains to 
common variant genetic risk, by integrating our results with previous GWAS of ADHD-
related behavior in the general population.
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Results
Genome-wide significantly associated ADHD risk loci
Genotype array data for 20,183 ADHD cases and 35,191 controls were collected from 12 
cohorts (Supplementary Table 1). These samples included a population-based cohort of 
14,584 cases and 22,492 controls from Denmark collected by the Lundbeck Foundation 
Initiative for Integrative Psychiatric Research (iPSYCH; Supplementary Figure 1), and 11 
European, North American and Chinese cohorts aggregated by the Psychiatric Genomics 
Consortium (PGC). ADHD cases in iPSYCH were identified from the national Psychiatric 
Central Research Register psychiatric and diagnosed by psychiatrists at a psychiatric 
hospital according to ICD10 (F90.0), and genotyped using Illumina PsychChip. Designs for 
the PGC cohorts have been described previously24,25,31,32,22 (see Supplementary 
Information for detailed cohort descriptions). All relevant ethical permissions and informed 
consent were obtained for the included cohorts (See Supplementary Information for dertails 
about approval authorities).
Prior to analysis, stringent quality control procedures were performed on the genotyped 
markers and individuals in each cohort using a standardized pipeline33 (Online Methods). 
Related individuals were removed, and genetic outliers within each cohort were excluded 
based on principal component analysis. Non-genotyped markers were imputed using the 
1000 Genomes Project Phase 3 reference panel34 (Online Methods).
GWAS was conducted in each cohort using logistic regression with the imputed additive 
genotype dosages. Principal components were included as covariates to correct for 
population stratification35 (Supplementary Information), and variants with imputation INFO 
score < 0.8 or minor allele frequency (MAF) < 0.01 were excluded. The GWAS were then 
meta-analyzed using an inverse-variance weighted fixed effects model36. The included 
single Chinese cohort had insufficient sample size for well-powered trans-ethnic modelling 
(Supplementary Figure 2). Association results were considered only for variants with an 
effective sample size greater than 70% of the full meta-analysis, leaving 8,047,421 variants 
in the final meta-analysis. A meta-analysis restricted to European-ancestry individuals 
(19,099 cases, 34,194 controls) was also performed to facilitate secondary analyses 
(Supplementary Information).
In total, 304 genetic variants in 12 loci surpassed the threshold for genome-wide significance 
(P<5×10−8; Figure 1, Table 1, Supplementary Figure 3). Results for the European ancestry 
meta-analysis were substantively similar (Supplementary Figure 4). No marker 
demonstrated significant heterogeneity between studies (Supplementary Figure 5 and 6) and 
no heterogeneity was observed between the Chinese and European ancestry cohorts 
(Supplementary Figure 2). Conditional analysis within each locus did not identify any 
independent secondary signals meeting genome-wide significance (Online Methods, 
Supplementary Table 2).
Homogeneity of effects between cohorts
No genome-wide significant heterogeneity was observed in the ADHD GWAS meta-analysis 
(Supplementary Information). Genetic correlation analysis (Online Methods) provided 
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further evidence that effects were consistent across cohort study designs. The estimated 
genetic correlation between the European ancestry PGC samples and the iPSYCH sample 
from LD score regression37 was not significantly less than one (rg = 1.17, SE = 0.20). The 
correlation between European ancestry PGC case/control and trio cohorts estimated with 
bivariate GREML was similarly close to one (rg = 1.02, SE = 0.32; Supplementary Table 3).
Polygenic risk scores (PRS)38 were also consistent across target samples. PRS computed in 
each PGC study using iPSYCH as the training sample were consistently higher in ADHD 
cases as compared to controls or pseudo-controls (Supplementary Figure 7). Increasing 
deciles of PRS in the PGC were associated with higher odds ratio (OR) for ADHD (Figure 
2). A similar pattern was seen in five-fold cross validation in the iPSYCH cohort, with PRS 
for each subset computed from the other four iPSYCH subsets and the PGC samples used as 
training samples (Online Methods; Figure 2). Across iPSYCH subsets, the mean of the 
maximum variance explained by the estimated PRS (Nagelkerke’s R2) was 5.5% (SE = 
0.0012) (Supplementary Figure 8). The difference in standardized PRS between cases and 
controls was stable across iPSYCH subsets (OR = 1.56, 95% confidence interval [CI]: 1.53 – 
1.60; Supplementary Figure 9) and across waves and PGC cohorts (Supplementary Figure 
10). These results further support the highly polygenic architecture of ADHD and 
demonstrate that ADHD risk is significantly associated with PRS in a dose-dependent 
manner.
Polygenic Architecture of ADHD
To assess the proportion of phenotypic variance explained by common variants we applied 
LD score regression37 to results from the European ancestry meta-analysis (Online 
Methods). Assuming a population prevalence of 5% for ADHD39, we estimate that the 
liability-scale SNP heritability h2snp = 0.216 (SE = 0.014, P = 8.18×10−54; Supplementary 
Table 4). These estimated polygenic effects account for 88% (SE = 0.0335) of observed 
genome-wide inflation of the test statistics in the meta-analysis (λ = 1.200; see 
Supplementary Figure 11 for quantile-quantile plots); the remaining inflation, which may 
reflect confounding factors such as cryptic relatedness and population stratification, is 
significant but modest (intercept=1.0362, SE = 0.0099, P=2.27 × 10−4).
To further characterize the patterns of heritability from the genome-wide association data, 
we partitioned SNP heritability by functional annotations as described in Finucane et al.40 
using partitioned LD Score regression (Online Methods). The analysis revealed significant 
enrichment in the heritability from SNPs located in conserved regions (P = 8.49 × 10−10; 
Supplementary Figure 12), supporting their biological importance. Enrichment of the SNP 
heritabilty in cell-type-specific regulatory elements was evaluated using the cell-type-
specific group annotations described in Finucane et al40. We observed a significant 
enrichment of the average per SNP heritability for variants located in central nervous system 
specific regulatory elements (enrichment = 2.44, SE = 0.35, P = 5.81 × 10−5; Supplementary 
Figures 13 and 14).
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Genetic correlation with other traits
Pairwise genetic correlation with ADHD was estimated for 219 phenotypes using LD score 
regression41,42 (Online Methods, Supplementary Data 1). Fourty-three phenotypes 
demonstrated significant genetic overlap with ADHD (P < 2.28 × 10−4), including major 
depressive disorder43, anorexia nervosa44, educational outcomes45–49, obesity-related 
phenotypes50–55, smoking56–58, reproductive success59, insomnia60, and mortality61 (Figure 
3; Supplementary Table 5). In most domains the genetic correlation is supported by GWAS 
of multiple related phenotypes. For the positive genetic correlation with major depressive 
disorder (rg = 0.42, P = 7.38 × 10−38), we also observe a positive correlation with depressive 
symptoms (rg = 0.45, P = 7.00 × 10−19), neuroticism (rg = 0.26, P= 1.02 × 10−8) and a 
negative correlation with subjective well-being (rg = −0.28, P = 3.73 × 10−9). The positive 
genetic correlations with ever smoked (rg = 0.48, P= 4.33 × 10−16) and with number of 
cigarettes smoked (rg = 0.45, P = 1.07 × 10−5) are reinforced by significant positive 
correlation with lung cancer (rg = 0.39, P= 6.35 × 10−10). Similarly, genetic correlations 
related to obesity include significant relationships with body mass index (BMI; rg = 0.26, P 
= 1.68 × 10−15), waist-to-hip ratio (rg = 0.30, P= 1.16 × 10−17), childhood obesity (rg = 0.22, 
P = 3.29 × 10−6), HDL cholesterol (rg = −0.22, P = 2.44 × 10−7), and Type 2 Diabetes (rg = 
0.18, P = 7.80 × 10−5). Additionally the negative correlation with years of schooling (rg = 
−0.53, P = 6.02 × 10−80) is supported by a negative genetic correlation with human 
intelligence (rg = −0.41, P = 7.03 × 10−26). Finally the genetic correlation with reproduction 
include a negative correlation with age of first birth (rg = −0.612, P = 3.70 × 10−61) and a 
positive correlation with number of children ever born (rg = 0.42, P = 8.51 × 10−17).
Biological annotation of significant loci
For the 12 genome-wide significant loci, Bayesian credible sets were defined to identify the 
set of variants at each locus most likely to include a variant with causal effect (Online 
Methods, Supplementary Data 2; Supplementary Table 6). Biological annotations of the 
variants in the credible set were then considered to identify functional or regulatory variants, 
common chromatin marks, and variants associated with gene expression (eQTLs) or in 
regions with gene interactions observed in Hi-C data (Online Methods, Supplementary Data 
3). Broadly, the significant loci do not coincide with candidate genes proposed to play a role 
in ADHD62.
Here we highlight genes that are identified in the regions of association (see also 
Supplementary Table 7). The loci on chromosomes 2, 7, and 10 each have credible sets 
localized to a single gene with limited additional annotations. In the chromosome 7 locus, 
FOXP2 encodes a forkhead/winged-helix transcription factor and is known to play an 
important role in synapse formation and neural mechanisms mediating the development of 
speech and learning63–65. Comorbidity of ADHD with specific developmental disorders of 
language and learning is common (7 – 11%)66,67, and poor language skills have been 
associated with higher inattention/hyperactivity symptoms in primary school68. On 
chromosome 10, the ADHD association is intronic, located in SORCS3, which encodes a 
brain-expressed transmembrane receptor that is important for neuronal development and 
plasticity69 and has previously been associated with depression43,70.
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Genome-wide significant loci on chromosomes 12 and 15 have more biological annotations 
supporting the co-localized genes. The credible set on chromosome 12 spans DUSP6, and 
includes an annotated missense variant in the first exon and an insertion near the 
transcription start site, though neither is the lead variant in the locus (Supplementary Data 
4). DUSP6 encodes a dual specificity phosphatase71, and may play a role in regulating 
neurotransmitter homeostasis by affecting dopamine levels in the synapses72,73. Regulation 
of dopamine levels is likely to be relevant to ADHD since widely used ADHD medications 
have dopaminergic targets74,75 that increase the availability of synaptic dopamine. The 
chromosome 15 locus is located in SEMA6D, and the majority of variants in the credible set 
are strongly associated with expression of SEMA6D in fibroblasts76. SEMA6D is active in 
the brain during embryonic development, and may play a role in neuronal wiring77. 
Furthermore, variants in SEMA6D have previously been associated with eduational 
attainment78.
Credible set annotations at the remaining loci are more diverse (Supplementary Data 3). The 
most strongly associated locus on chromosome 1 (index variant rs112984125) covers a 
gene-rich 250kb region of strong LD. The index variant is intronic to ST3GAL3, and most 
SNPs in the credible set are strongly associated with expression of ST3GAL3 in whole 
blood79 (Supplementary Data 3). Missense mutations in ST3GAL3 have been shown to 
cause autosomal recessive intellectual disability80. Hi-C and eQTL annotations suggest 
multiple alternative genes however, including PTPRF (Supplementary Data 4). The locus 
also includes an intergenic variant, rs11210892, that has previously been associated with 
schizophrenia33.
On chromosome 5, the credible set includes links to LINC00461 and TMEM161B 
(Supplementary Data 3). The function of LINC00461 is unclear, but the RNA has highly 
localized expression in the brain81 and the genome-wide significant locus overlaps with 
variants in LINC00461 associated with educational attainment78. Alternatively, a genome-
wide significant SNP in this locus (rs304132) is located in MEF2C-AS1, of strong interest 
given previous associations between MEF2C and severe intellectual disability,82–84 cerebral 
malformation83, depression70, schizophrenia33 and Alzheimer’s disease85, but the 
corresponding variant is not supported by the credible set analysis. Credible set annotations 
for other significant loci are similarly cryptic.
Analysis of gene sets
Competitive gene based tests were performed for FOXP2 target genes, highly constrained 
genes, and for all Gene Ontology terms86 from MsigDB 6.087 using MAGMA88 (Online 
Methods). Association results for individual genes are consistent with the genome-wide 
significant loci for the GWAS (Supplementary Table 8), however four new genes passed the 
threshold for exome-wide significant association (Supplementary Figure 15a–d). Three 
independent sets of FOXP2 downstream target genes89,90 were tested (Online Methods), 
none of which demonstrated significant association to ADHD (Supplementary Table 9). The 
lack of association may be caused by unknown functions of FOXP2 driving ADHD risk, 
insufficient power to detect relevant downstream genes, or because only a small subset of 
biological functions regulated by FOXP2 are relevant to ADHD pathogenesis.
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Consistent with the partitioning of heritability, a set of 2,932 genes that are highly 
constrained and show high intolerance to loss of function91 showed significant association 
with ADHD (β = 0.062, P = 2.6 × 10−4; Supplementary Table 10). We also find little 
evidence for effects in previously proposed candidate genes for ADHD62; of the nine 
proposed genes only SLC9A9 showed weak association with ADHD (P = 3.4 × 10−4; 
Supplementary Table 11). None of the Gene Ontology gene sets were significant after 
correcting for multiple testing, although the most associated included interesting nominally 
significant pathways such as “dopamine receptor binding” (P = 0.0010) and “Excitatory 
Synapse” (P = 0.0088; Supplementary Data 5).
Replication of GWAS loci
For replication we evaluated the comparison of the GWAS meta-analysis of ADHD with 
three other independent ADHD-related GWASs: replication of top loci in an Icelandic 
cohort with ADHD status derived from medical records of ICD codes and medication 
history by deCODE (5,085 cases, 131,122 controls), a GWAS of self-reported ADHD status 
among 23andMe research participants (5,857 cases, 70,393 controls) and a meta-analysis of 
GWAS of childhood rating scales of ADHD symptoms performed by the EAGLE 
consortium (17,666 children < 13 years of age)30 and QIMR92 (2,798 adolescents), referred 
to as EAGLE/QIMR throughout the text. Although the phenotyping and cohort 
ascertainment of the 23andMe and EAGLE/QIMR studies differ from the PGC and iPSYCH 
ADHD meta-analysis (Supplemenatry Information), they have clear relevance to 
understanding how the ADHD GWAS results generalize to closely related phenotypes.
Top loci from the ADHD GWAS showed moderate concordance across the three replication 
studies. Sign concordance between each of the three replication cohorts and the ADHD 
GWAS was significantly greater than would be expected by chance (range 72–82% 
concordant; P < 0.0167 = 0.05/3 replication cohorts; Supplementary Table 12) for nominally 
associated loci from the ADHD GWAS (P < 1 × 10−6), with the highest concordance 
observed in EAGLE/QIMR. The deCODE and 23andMe results also permit direct 
comparisons of the magnitude of effect sizes for the top loci in the ADHD loci 
(Supplementary Table 13). Regressing effect size estimates from each replication cohort on 
estimates from the ADHD GWAS adjusted for winner’s curse yields significantly positive 
slopes (deCODE slope = 0.664, P = 1.2 × 10−4; 23andMe slope = 0.417, P = 1.11 × 10−3), 
although these slopes are less than one, suggesting imperfect replication. Among the 
genome-wide significant loci, rs9677504 (SPAG16 locus) in deCODE and rs112984125 
(ST3GAL3/PTPRF locus) and rs212178 (LINC01572 locus) in 23andMe are noteable 
outlers with weak replication results (Online Methods, Supplementary Figure 16–17).
The genome-wide data available from 23andMe and EAGLE/QIMR showed similar trends 
for replication. The genetic correlation between EAGLE/QIMR and the ADHD GWAS was 
extremely strong (rg = 0.970, SE = 0.207, P = 2.66 × 10−6) and not significantly different 
from one (one-sided P = 0.442). Genetic correlation with 23andMe was weaker but still 
strongly positive (rg = 0.653, SE = 0.114, P = 1.11 × 10−8), although also significantly less 
than 1 (one-sided P= 1.17 × 10−3). To explore this lower correlation we evaluated the genetic 
correlation between 23andMe and traits from LD Hub (see URLs)42 to potentially identify 
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differences in the profile of genetic correlation compared to the ADHD GWAS (Online 
Methods). This comparison identified striking differences (Supplementary Table 14), most 
notably that the 23andMe GWAS show little to no genetic correlation with college 
completion (rg = 0.056, compared to rg = −0.54 for the primary ADHD GWAS; approximate 
P = 1.1 × 10−9 for difference) and other education-related phenotypes. Genetic correlations 
with obesity-related phenotypes were similarly smaller for the 23andMe cohort. The one 
domain where 23andMe exhibited a trend toward stronger genetic correlations were 
schizophrenia (rg = 0.27, vs. rg = 0.12 in ADHD, P = 0.053) and bipolar disorder (rg = 0.029, 
vs. rg = 0.095 in ADHD, P = 0.09), though these trends are not significant with the 
approximated test of the difference in genetic correlation.
Finally, we meta-analyzed the ADHD GWAS with each replication cohort. For EAGLE/
QIMR, we developed a novel model to meta-analyze the GWAS of the continuous measure 
of ADHD with the clinical diagnosis in the ADHD GWAS. In brief, we perform a Z-score 
based meta-analysis using a weighting scheme derived from the SNP heritability and 
effective sample size for each phenotype that fully accounts for the differences in 
measurement scale (detailed description in Supplementary Information, and Supplementary 
Figures 18–20). This calibration based on the genome-wide estimate of heritability prevents 
joint meta-analysis of all replication cohorts since genome-wide data is not available for the 
deCODE study.
Meta-analyses of the ADHD GWAS with each replication study identified 10 genome-wide 
significant loci (P < 5 × 10−8, without multiple testing correction) in meta-analysis with 
deCODE, 10 significant loci with 23andMe, and 15 significant loci with EAGLE/QIMR 
(Supplementary Data 6, Supplementary Figures 21–22). Of the 12 significant loci from the 
primary ADHD GWAS, four were significant in all three of these replication meta-analyses: 
index variants rs11420276 (ST3GAL3/PTPRF), rs5886709 (FOXP2), rs11591402 
(SORCS3), and rs1427829 (intergenic). The remaining loci were all significant in at least 
one of the replication meta-analyses. In addition, ten novel loci reached genome-wide 
significance in the replication meta-analyses, of which three loci were significant in two of 
these analyses (Supplementary Data 6): index variants rs1592757 / rs30266 (Refseq 
LOC105379109), rs28452470 / rs1443749 (CADPS2), and rs2243638 / rs9574218 
(RNF219-AS1). The CADPS2 locus has recently been identified in autism spectrum 
disorder as a novel locus shared with educational attainment93.
Meta-analysis with the 23andMe cohort also found genome-wide significant heterogeneity at 
the lead Chromosome 1 locus from the ADHD GWAS meta-analysis (rs12410155: I2 = 97.2, 
P = 2.29 × 10−9; Supplementary Figures 23–24). This heterogeneity is consistent with the 
moderate sign concordance, effect size replication, and genetic correlation of the 23andMe 
cohort with the ADHD GWAS. Notably, the lead chromosome 1 locus in the ADHD GWAS 
URLs
LD-Hub: http://ldsc.broadinstitute.org/ldhub/
LD score regression: https://github.com/bulik/ldsc
Pre-computed European LD scores: https://data.broadinstitute.org/alkesgroup/LDSCORE/
PGC Ricopili GWA pipeline: https://github.com/Nealelab/ricopili
Credible set analysis: https://github.com/hailianghuang/FM-summary
FUMA: http://fuma.ctglab.nl
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overlaps a reported association with educational attainment78, suggesting this heterogeneity 
is consistent with the much weaker genetic correlation between the 23andMe results and 
published GWAS of education-related outcomes. No genome-wide significant heterogeneity 
was observed in the replication meta-analyses with deCODE or EAGLE/QIMR 
(Supplementary Figures 25–26, Supplementary Data 6).
Discussion
GWAS meta-analysis of ADHD revealed the first genome-wide significant risk loci, and 
indicates an important role for common variants in the polygenic architecture of ADHD. 
Several of the loci are located in or near genes that implicate neurodevelopmental processes 
that are likely to be relevant to ADHD, including FOXP2, SORCS3, and DUSP6. Future 
work may focus on refining the source of the strong association in each locus, especially the 
lead locus on chromosome 1 which is complicated by broad LD and substantial 
heterogeneity between ADHD the main meta-analysis and analysis of self-reported ADHD 
status in 23andMe.
The 12 significant loci are compelling, but only capture a tiny fraction of common variant 
risk for ADHD. The odds ratios for the risk increasing allele at the index SNPs in the 12 
significant loci are modest, ranging from 1.077 to 1.198 (Table 1). This is within the range 
of effect sizes for common genetic variants that has been observed for other highly 
polygenic psychiatric disorders e.g. schizophrenia33. A considerably larger proportion of the 
heritability of ADHD can be explained by all common variants (h2snp = 0.22, SE = 0.01). 
This is consistent with previous estimates of h2snp for ADHD in smaller studies (h2snp: 0.1 – 
0.28)23,24, and also comparable to SNP heritability estimates for schizophrenia (h2snp 0.23 – 
0.26)23,24. As would be hypothesized for a psychiatric disorder, these effects are enriched in 
conserved regions and regions containing enhancers and promoters of expression in central 
nervous system tissues, consistent with previous observations in schizophrenia and bipolar 
disorder40. On the other hand, we do not observe substantial effects in most previously 
reported candidate genes for ADHD62.
Along with polygenicity, selection and evolutionary pressures may be an important feature 
of the architecture of ADHD genetics. We observe that ADHD risk variants are strongly 
enriched in genomic regions conserved in mammals94, and constrained genes likely to be 
intolerant of loss-of-function mutations91 are associated with ADHD. We also find that 
common variant risk for ADHD is genetically correlated with having children younger and 
having more children, in line with epidemiological findings of increased risky sexual 
behaviour95–97 and increased risk of ADHD for children born to young parents98–100. Given 
the phenotypic101,102 and genetic103 correlation of ADHD with reduced educational 
attainment, positive selective pressure on the genetics of ADHD would be consistent with 
recent work suggesting that variants associated with educational attainment are under 
negative selection in Iceland104. Future studies of fecundity and the role of rare and de novo 
variants in ADHD may provide more insight on selective pressures in ADHD-associated 
loci.
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The observed genetic correlations with educational outcomes and other phenotypes suggest 
a strong genetic component to the epidemiological correlates of ADHD. The significant 
positive genetic correlation of ADHD with major depressive disorder and depressive 
symptoms supports previous findings suggesting a positive genetic overlap between those 
phenotypes24,42, as well as the broader genetic overlap of psychiatric disorders23,24. Positive 
genetic correlations between ADHD and health risk behaviors such as smoking and obesity 
are consistent with the observed increase in those behaviors among individuals with 
ADHD105–108 and are indicative of a shared genetic basis for these traits. We also observe a 
positive genetic correlation of ADHD with insomnia, consistent with reports of sleep 
disturbances in ADHD109, but this relationship does not appear to generalize to other sleep-
related phenotypes.
These genetic correlations may not generalize to all settings. We observe much weaker 
genetic correlation of the 23andMe ADHD results with educational attainment, with only 
partial genetic correlation between 23andMe and the current ADHD GWAS, including 
significant heterogeneity in the lead chromosome 1 locus. The pattern of replication for the 
top loci in the deCODE study is stronger but still mixed. These differences may reflect 
dissimilarities in phenotyping (e.g. self-report vs. medical records), exclusion of individuals 
with comorbid psychiatric disorders (deCODE), study population (e.g. higher average 
education and socio-economic status among 23andMe research participants possibly under-
representing the proportion of individuals with ADHD with poor educational outcomes in 
the general population), or other study factors that should be a focus of future work.
On the other hand, the replication results from EAGLE30/QIMR92 are much stronger and 
support the hypothesis that ADHD is the extreme expression of one or more heritable 
quantitative traits110. We observe strong concordance between the GWAS of ADHD and the 
previous GWASs of ADHD-related traits in the population, both in terms of genome-wide 
genetic correlation and concordance at individual loci. Polygenic risk for ADHD has 
previously been associated with inattentive and hyperactive/impulsive trait variation below 
clinical thresholds in the population29. Shared genetic risk with health risk behaviors may 
similarly be hypothesized to reflect an impaired ability to self-regulate and inhibit impulsive 
behavior111,112. The observed negative correlation between ADHD and anorexia nervosa 
may also be related to these behavioral factors.
In summary, we report 12 independent genome-wide significant loci associated with ADHD 
in GWAS meta-analysis of 55,374 individuals from 12 study cohorts. The GWAS meta-
analysis implicates FOXP2 and other biologically informative genes as well as constrained 
regions of the genome as important contributors to the etiology of ADHD. The results also 
highlight strong overlap with the genetics of ADHD-related traits and health risk behaviors 
in the population, encouraging a dimensional view of ADHD as the extreme end of a 
continuum of symptoms.
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Online Methods
GWAS meta-analysis
Quality control, imputation and primary association analyses were done using the 
bioinformatics pipeline Ricopili (see URLs), developed by the Psychiatric Genomics 
Consortium (PGC)33. In order to avoid potential study effects the 11 PGC samples and the 
23 genotyping batches within iPSYCH were each processed separately unless otherwise 
stated (Supplementary Information).
Stringent quality control was applied to each cohort following standard procedures for 
GWAS, including filters for call rate, Hardy-Weinberg equilibrium, and heterozygosity rates 
(Supplementary Information). Each cohort was then phased and imputed using the 1000 
Genomes Project phase 3 (1KGP3)34,113 imputation reference panel using SHAPEIT114 and 
IMPUTE2115, respectively. For trio cohorts, pseudocontrols were defined from phased 
haplotypes prior to imputation.
Cryptic relatedness and population structure were evaluated using a set of high quality 
markers pruned for linkage disequilibrium (LD). Genetic relatedness was estimated using 
PLINK v1.9116,117 to identify first and second-degree relatives (π > 0.2) and one individual 
was excluded from each related pair. Genetic outliers were identified for exclusion based on 
principal component analyses using EIGENSOFT35,118. This was done separately for each 
of the PGC cohorts and on a merged set of genotypes for the iPSYCH cohort 
(Supplementary Information). Across studies, a total of 20,183 cases and 35,191 controls 
remained for analysis after QC.
Genome-wide association analyses for the 11 PGC samples and the 23 waves in iPSYCH 
were performed using logistic regression model with the imputed marker dosages in PLINK 
v1.9116,117. Principal components were included as covariates to control for population 
stratification35,118, along with relevant study-specific covariates where applicable 
(Supplementary Information, Supplementary Table 1). Subsequently the results were meta-
analysed using an inverse-variance weighted fixed effects model, implemented in METAL 
(version 2011–03–25)36. Variants were filtered and included if imputation quality (INFO 
score) was > 0.8 and MAF > 0.01. Only markers supported by an effective sample size Neff 
= 4/(1/Ncases + 1/Ncontrols)119 greater than 70% were included. After filtering, the meta-
analysis included results for 8,047,421 markers.
Conditional analysis
Twelve independent genome-wide significant loci were identified by LD clumping and 
merging loci within 400 kb (Supplementary Information). In two of these loci a second 
index variant persisted after LD clumping. The two putative secondary signals were 
evaluated by considering analysis conditional on the lead index variant in each locus. In each 
cohort, logistic regression was performed with the imputed genotype dosage for the lead 
index variant included as a covariate. All covariates from the primary GWAS (e.g. principal 
components) were also included. The conditional association results were then combined in 
an inverse-variance weighted meta-analysis.
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Genetic correlations between ADHD samples
Genetic correlation between the European-ancestry PGC and iPSYCH GWAS results was 
calculated using LD Score regression37. The regression was performed using pre-computed 
LD scores for HapMap3 SNPs calculated based on 378 European-ancestry individuals from 
the 1000 Genomes Project (see URLs). Only results for markers with an imputation INFO 
score > 0.90 were included in the analysis. In addition, a bivariate GREML analysis was 
conducted using GCTA120 in order to estimate the genetic correlation between PGC case/
control and trio study designs.
Polygenic Risk Scores for ADHD
The iPSYCH sample were split into five groups, and subsequently five leave-one-out 
association analyses were conducted, using four out of five groups and the PGC samples as 
training datasets38. PRS were estimated for each target sample using variants passing a range 
of association P-value thresholds in the training samples. PRS were calculated by 
multiplying the natural log of the odds ratio of each variant by the allele-dosage (imputation 
probability) and whole-genome polygenic risk scores were obtained by summing values over 
variants for each individual.
For each of the five groups of target samples, PRS were normalized and the significance of 
the case-control score difference was tested by standard logistic regression including 
principal components. For each target group and for each P-value threshold the proportion of 
variance explained (i.e. Nagelkerke’s R2) was estimated by comparing the regression with 
PRS to a reduced model with covariates only. The OR for ADHD within each PRS decile 
group was estimated based on the normalized score across groups (using the P-value 
threshold with the highest Nagelkerke’s R2 within each target group) (Figure 3). OR was 
also estimated using logistic regression on the continuous scores for each target group 
separately and an OR based on all samples using the normalized PRS score across all groups 
(Supplementary Figure 9). Additionally PRS were evaluated in the PGC samples using the 
iPSYCH sample as training sample, following the approach described above (Supplementary 
Information).
SNP heritability and intercept evaluation
LD score regression37 was used to evaluated the relative contribution of polygenic effects 
and confounding factors, such as cryptic relatedness and population stratification, to 
deviation from the null in the genome-wide distribution of GWAS χ2 statistics. Analysis was 
performed using pre-computed LD scores from European-ancestry samples in the 1000 
Genomes Project (see URLs) and summary statistics for the European-ancestry ADHD 
GWAS to ensure matching of population LD structure. The influence of confounding factors 
was tested by comparing the estimated intercept of the LD score regression to one, it’s 
expected value under the null hypothesis of no confounding from e.g. population 
stratification. The ratio between this deviation and the deviation of the mean χ2 from one 
(i.e. it’s expected value under the null hypothesis of no association) was used to estimate the 
proportion of inflation in χ2 attributable to confounding as opposed to true polygenic effects 
(ratio = (intercept-1)/(mean χ2-1)). SNP heritability was estimated based on the slope of the 
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LD score regression, with heritability on the liability scale calculated assuming a 5% 
population prevalence of ADHD39.
Partitioning of the heritability
SNP heritability was partitioned by functional category and tissue association using LD 
score regression40. Partitioning was performed for 53 overlapping functional categories, as 
well as 220 cell-type-specific annotations grouped into 10 cell-type groups, as described in 
Finucane et al. 40. For both sets of annotations we used previously computed LD scores and 
allele frequencies from European ancestry samples in the 1000 Genomes Project (available 
on see URLs).
Additionally we expanded the cell-type specific heritability analysis by including an 
annotation based on information about H3K4Me1 imputed gapped peaks excluding the 
broad MHC-region (chr6:25–35MB), generated by the Roadmap Epigenomics Mapping 
Consortium121,122 (Supplementary Information). The analyses were restricted to the 
European GWAS meta-analysis results to ensure matching of population LD structure. 
Results for each functional category were evaluated based on marginal enrichment, defined 
as the proportion of SNP heritability explained by SNPs in the annotation divided by the 
proportion of genome-wide SNPs in the annotation40. For each cell-type group and each 
H3K4Me1 cell-type annotations, the contribution to SNP heritability was tested conditional 
on the baseline model containing the 53 functional categories.
Genetic correlations of ADHD with other traits
The genetic correlations of ADHD with other phenotypes were evaluated using LD Score 
regression42. For a given pair of traits, LD score regession estimates the expected population 
correlation between the best possible linear SNP-based predictor for each trait, restricting to 
common SNPs. Such correlation of genetic risk may reflect a combination of colocalization, 
pleiotropy, shared biological mechanisms, and causal relationships between traits. 
Correlations were tested for 211 phenotypes with publically available GWAS summary 
statistics using LD Hub41 (Supplementary Information; see URLs). Additonally, we 
analysed on our local computer cluster, the genetic correlation of ADHD with eight 
phenotypes: human intelligence103, four phenotypes related to education and cognition 
analyzed in samples from the UK_Biobank49 (college/university degree, verbal–numerical 
reasoning, memory and reaction time), insomnia60, anorexia nervosa44, and major 
depressive disorder43. The genetic correlation with major depressive disorder was tested 
using GWAS results from an updated analysis of 130,664 cases with major depressive 
disorder and 330,470 controls from the Psychiatric Genomics Consortium. As in the 
previous LD score regression analyses, this estimation was based on summary statistics from 
the European GWAS meta-analysis, and significant correlations reported are for traits 
analysed using individuals with European ancestry.
Credible set analysis
We defined a credible set of variants in each locus using the method described by Maller et 
al.123 (Supplementary Information), implemented by a freely available R script (see URLs). 
Under the assumption that (a) there is one causal variant in each locus, and (b) the causal 
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variant is observed in the genotype data, the credible set can be considered to have a 99% 
probability of containing the causal variant. For each the 12 genome-wide significant loci, 
variants within 1MB and in LD with correlation r2 > 0.4 to the index variant were considered 
for inclusion in the credible set analysis. The credible set analysis was done using the 
European GWAS meta-analysis to ensure consistent LD structure in the analyzed cohorts.
Biological annotation of variants in credible set
The variants in the credible set for each locus, were annotated based on external reference 
data in order to evaluate potential functional consequences. In particular, we identify: (a) 
Gene and regulatory consequences annotated by Variant Effect Predictor (VEP) using 
Ensembl with genome build GRCh37124. We exclude upstream and downstream 
consequences, and consequences for transcripts that lack a HGNC gene symbol (e.g. vega 
genes). (b) Variants within 2kb upstream of the transcription start site (TSS) of at least one 
gene isoform based on Gencode v19125. (c) Variants annotated as interacting with a given 
gene in Hi-C data from samples of developing human cerebral cortex during neurogenesis 
and migration126. Annotations are considered for both the germinal zone (GZ), primarily 
consisting of actively dividing neural progenitors, and the cortical and subcortical plate 
(CP), primarily consisting of post-mitotic neurons. (d) Variants identified as eQTLs based on 
gene expression in GTEx127 or BIOS79. Expression quantitative trait loci were annotated 
using FUMA (see URLs). We restricted to eQTL associations with false discovery fate 
(FDR) < 1e-3 within each dataset. (e) Chromatin states of each variant based on the 15-state 
chromHMM analysis of epigenomics data from Roadmap128. The 15 states summarize to 
annotations of active chromatin marks (i.e. Active TSS, Flanking Active TSS, Flanking 
Transcription, Strong Transcription, Weak Transcription, Genic Enhancer, Enhancer, or Zinc 
Finger [ZNF] gene), repressed chromatin marks (Heterochromatin, Bivalent TSS, Flanking 
Bivalent TSS, Bivalent Enhancer, Repressed Polycomb, or Weak Repressed Polycomb), or 
quiescent. The most common chromatin state across 127 tissue/cell types was annotated 
using FUMA (see URLs). We also evalauted the annotated chromatin state from fetal brain.
Gene-set analyses
Gene-based association with ADHD was estimated with MAGMA 1.0588 using the 
summary statistics from the European GWAS meta-analysis (Ncases = 19,099, Ncontrols = 
34,194; Supplementary Information, Supplementary Information Table 1). Association was 
tested using the SNP-wise mean model, in which the sum of -log(SNP P-value) for SNPs 
located within the transcribed region (defined using NCBI 37.3 gene definitions) was used 
as the test statistic. MAGMA accounts for gene-size, number of SNPs in a gene and LD 
between markers when estimating gene-based P-values. LD correction was based on 
estimates from the 1000 genome phase 3 European ancestry samples34.
The generated gene-based P-values were used to analyze sets of genes in order to test for 
enrichment of association signals in genes belonging to specific biological pathways or 
processes. In the analysis only genes on autosomes, and genes located outside the broad 
MHC region (hg19:chr6:25–35M) were included. We used the gene names and locations and 
the European genotype reference panel provided with MAGMA. For gene sets we used sets 
with 10–1000 genes from the Gene Ontology sets86 currated from MsigDB 6.087.
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Targeted FOXP2 downstream target gene sets were analysed for association with ADHD. 
Three sets were examined: 1) Putative target genes of Foxp2 that were enriched in wild type 
compared to control Foxp2 knockout mouse brains in ChIP-chip experiments (219 genes), 2) 
Genes showing differential expression in wild type compared to Foxp2 knockout mouse 
brains (243 genes), and 3) FOXP2 target genes that were enriched in either or both basal 
ganglia (BG) and inferior frontal cortex (IFC) from human fetal brain samples in ChIP-chip 
experiments (258 genes). Curated short lists of high-confidence genes were obtained from 
Vernes et al.89 and Spiteri et al90.
A set of evolutionarily highly constrained genes were also analysed. The set of highly 
constrained genes was defined using a posterior probability of being loss-of-function 
intolerant (pLI) based on the observed and expected counts of protein-truncating variants 
(PTV) within each gene in a large study of over 60,000 exomes from the Exome 
Aggregation Consortium (ExAC)91. Genes with pLI ≥0.9 were selected as the set of highly 
constrained genes (2932 genes).
Replication of GWAS loci
To replicate the results of the ADHD GWAS meta-analysis we compared the results to 
analyses of cohorts from deCODE and 23andMe, and a meta-analysis of two independent 
studies conducted by EAGLE and QIMR (referred to as EAGLE/QIMR). We evaluated 
evidence for replication based on: (a) sign tests of concordance between the ADHD GWAS 
meta-analysis and each replication cohort; (b) comparison of bias-corrected effect sizes 
between the ADHD GWAS and the deCODE and 23andMe replication cohorts; (c) genetic 
correlation between the ADHD GWAS and the 23andMe and EAGLE/QIMR replication 
cohorts; (d) meta-analysis of the ADHD GWAS meta-analysis results with the results from 
each replication cohort; and (e) tests of heterogeneity between the ADHD GWAS and each 
replication cohorts.
For the sign test, we first identified the overlapping SNPs present in the ADHD GWAS and 
each of the three replication analyses (i.e. deCODE, 23andMe, and EAGLE/QIMR). For 
each replication cohort intersecting SNPs were then clumped for LD (r2 > 0.05 within 1 Mb) 
for all variants with P < 1 × 10−4 in the ADHD GWAS (or P < 1 × 10−5 for the deCODE 
replication) using 1000 Genomes Phase 3 data on European ancestry populations. After 
clumping, sign tests were performed to test the proportion of loci with a concordant 
direction of effect in the replication cohort (π) using a one sample test of the proportion with 
Yates’ continuity correction129 against a null hypothesis of π = 0.50 (i.e. the signs are 
concordant between the two analyses by chance) in R130. This test was evaluated separately 
for concordance in deCODE, 23andMe, and EAGLE/QIMR for loci passing P-value 
thresholds of P < 5 × 10−8 (i.e. genome-wide significant loci), P < 1 × 10−7, P < 1 × 10−6, P 
< 1 × 10−5, and P < 1 × 10−4 in the ADHD GWAS meta-analysis (Supplementary 
Information).
In addition to testing concordance for the direction of effect, we also evaluate replication for 
the magnitude of the effect sizes. Specifically, for each of deCODE and 23andMe we 
regressed the effect size in the replication cohort (i.e. the log odds ratio) on the estimated 
effect size from the ADHD GWAS after adjustment for winner’s curse for loci with P < 
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1e-6. Winner’s curse correction is perfomed by computing posterior mean estimates of 
marginal SNP effects β j after fitting a spike-and-alab distribution
β j
0
N 0, τ2
with probabilityπ
otherwise
by maximum likelihood as described by Okbay et al.78 (Supplementary Information). For 
the regression of effect sizes we oriented all variants in the direction of the risk increasing 
allele estimated from the ADHD GWAS, constrained the intercept to zero, and weighted the 
variants proportional to the inverse of their squared standard error from the ADHD GWAS. 
A regression slope of one indicates “ideal” replication of all loci in the regression, whereas a 
slope of zero indicates no replication.
Genetic correlation of the ADHD GWAS with the 23andMe and EAGLE/QIMR results was 
computed using LD score regression37 with pre-computed European ancestry LD scores 
following the same procedure as described above for other genetic correlation analyses. 
Genetic correlation could not be computed for deCODE since results were only available for 
top loci from the ADHD GWAS. To further explore the moderate genetic correlation 
between the 23andMe results and the ADHD GWAS we also evaluated the genetic 
correlation between 23andMe and traits from LD Hub (see URLs)42. To evaluate the 
magnitude of the observed differences in rg we consider both the absolute difference (i.e. 
rg, ADHD − rg, 23andMe ) and the test of an approximate Z score for this difference 
(Supplementary Information):
Z =
rg, ADHD − rg, 23andMe
SEADHD
2 + SE23andMe
2
We do not expect this to be an ideal formal test for the difference between two genetic 
correlations, and therefore emphasize caution in interpreting the precise results. 
Nevertheless, it does offer a useful benchmark for evaluating the magnitude of the difference 
between the rg estimates in the context of the uncertainty in those values.
Finally, we meta-analyzed the ADHD GWAS with the results from each replication cohort. 
For deCODE and 23andMe inverse variance-weighted meta-analyses were performed. For 
meta-analysis with the EAGLE/QIMR GWAS of ADHD-related behaviors in childhood 
population samples we used a modified sample size-based weighting method. Modified 
sample size-based weights were derived to accounts for the respective heritabilities, genetic 
correlation, and measurement scale of the GWASs (Supplementary Information). To 
summarize, given z-scores Z1j and Z2j resulting from GWAS of SNP j in a dichotomous 
phenotype (e.g. ADHD) with sample size NI and a continuous phenotype (e.g. ADHD-
related traits) with sample size N2, respectively, we calculate
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Z j,meta =
N1 jZ1 j + N2 jZ2 j
N1 j + N2 j
where
Z2 j = sign rg   
Z2 j
1 + 1 − rg
2 N2 jh2
2l j/M
N1 j = N1 j
P 1 − P ϕ Φ−1 K 2
K 1 − K 2
N2 j = N2 j
rg
2h2
2/h1
2
1 + 1 − rg
2 N2 jh2
2l j/M
The adjusted sample sizes N1 and N2 reflect differences in power between the studies due to 
measurement scale and relative heritability that is not captured by sample size. The 
calculation of Z2 reduces the contribution of the continuous phenotype’s GWAS to the meta-
analysis based on imperfect genetic correlation with the dichotomous phenotype of interest 
(i.e. ADHD). The adjustments are computed based on the sample prevalence (P) and 
population prevalence (K) of the dichotomous phenotype, the estimated liability scale SNP 
heritability of the two phenotypes (h12 and h22), and the genetic correlation (rg) between the 
two phenotypes, as well as the average SNP LD score (lj) and the number of SNPs (M). 
Heritability and genetic correlation values to compute these weights are computed using LD 
score regression. This meta-analysis weighting scheme is consistent with weights 
alternatively derived based on modelling the joint distribution of marginal GWAS beta 
across traits131.
To test heterogeneity with each replication cohort, we considered Cochran’s Q test of 
heterogeneity in the meta-analyses. Specifically, we evaluated the one degree of freedom test 
for heterogeneity between the ADHD GWAS meta-analysis and the replication cohort.
Data Avalibility Statement
The PGC’s policy is to make genome-wide summary results public. Summary statistics with 
the results from the ADHD GWAs meta-analysis of iPSYCH and the PGC samples are 
available on the PGC website (https://www.med.unc.edu/pgc/results-and-downloads). GWA 
summary statistics with results from the GWAS of ADHD symptom scores analyzed in the 
EAGLE sample can be accessed at the PGC website (see link above). Summary statistics for 
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the 23andMe dataset can be obtained by qualified researchers under an agreement with 
23andMe that protects the privacy of the 23andMe participants.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Manhattan plot of the results from the GWAS meta-analysis of ADHD.
The index variants in the 12 genome-wide significant loci are highlighted as a green 
diamond. Index variants located with a distance less than 400kb are considered as one locus. 
The y-axis represents –log(two-sided P-values) for association of variants with ADHD, from 
meta-analysis using an inverse-variance weighted fixed effects model, and a total sample 
size of 20,183 ADHD cases and 35,191 controls. The vertical red line represents the 
threshold for genome-wide significance.
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Figure 2. Odds Ratio by PRS for ADHD
Odds Ratio (OR) by PRS within each decile estimated for n = 18,298 biological independent 
individuals in the PGC samples (red dots) and in n = 37,076 biological independent 
individuals in the iPSYCH sample (blue dots). PRSs in the iPSYCH sample were obtained 
by five leave-one-out analyses, using 4 of 5 groups as training datasets for estimation of SNP 
weights, while estimating Polygenic Risk Scores (PRS) for the remaining target group. Odds 
ratios and 95% confidence limits (error bars) were estimated using logistic regression on the 
continuous scores.
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Figure 3. Genetic correlations of ADHD with other phenotypes
Significant genetic correlations between ADHD (results from Europena GWAS meta-
analysis of 19,099 cases, 34,194 controls) and other traits reveal overlap of genetic risk 
factors for ADHD across several groups of traits (grouping indicated by a horizontal line): 
educational, psychiatric/personality, weight (and possible weight related traits), smoking 
behaviour/smoking-related cancer, reproductive traits and parental longevity (Sample size of 
the external GWASs are presented in Supplementary Table 5). In total 219 traits were tested 
and only traits significant after Bonferroni correction are presented in the figure. Two 
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significant educational phenotypes are omitted due to substantial overlap with years of 
schooling. Genetic correlation is presented as a dot and error bars indicate 95% confidence 
limits.
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